Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.43 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 4/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.43 |
| ▸ | PDE5A | O76074 | 4/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892389 | 0.80 | TYMP (0.43) | PDE3BPDE3AMAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL2897883 | 0.80 | TYMP (0.50) | PDE3BPDE3APDE1APDE1BPDE1C | |
| SCHEMBL2899212 | 0.70 | TYMP (0.45) | PTGS1NPSR1TYMPALDH1A1P2RX4 | |
| SCHEMBL31621004 | 0.70 | TYMP (0.60) | TYMPALDH1A1P2RX4RAB9ANPC1 | |
| SCHEMBL3015728 | 0.69 | TYMP (0.54) | TYMPALDH1A1P2RX4RAB9ANPC1 | |
| SCHEMBL3695457 | 0.67 | LMNA (0.46) | PDE3BPDE3AMAPK1PTGS1PDE1A | |
| SCHEMBL2745392 | 0.67 | TYMP (0.45) | TYMPCYP2C19ALDH1A1P2RX4RAB9A | |
| SCHEMBL599845 | 0.67 | TYMP (0.45) | TYMPP2RX4RAB9ANPC1MEN1 | |
| SCHEMBL2189433 | 0.67 | TYMP (0.53) | MAPK1NPSR1TYMPCYP2C9CYP2C19 | |
| SCHEMBL11792243 | 0.66 | P2RX4 (0.59) | TYMPCYP2C19ALDH1A1P2RX4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217168-B2 | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-8217168-B2 | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-8217168-B2 | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| EP-2205560-B1 | AZABICYCLO [3. 1. 0]HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2011-12-28 | — | — | EP | disclosed |
| EP-2205560-B1 | AZABICYCLO [3. 1. 0]HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2011-12-28 | — | — | EP | disclosed |
| US-20100240661-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-20100240661-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-20100240661-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| EP-2205560-A1 | AZABICYCLO Ý3. 1. 0¨HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | Glaxo Group Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009043884-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043884-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240661-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, CHRNA5, NR3C2 | PDE3B 1442/4885PDE3A 949/4885MAP2K4 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.